Phase I study combining tumor necrosis factor with interferon-α and interleukin-2

Elhamy D. Eskander, Harold Harvey, Elise Givant, Allan Lipton

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We evaluated the effects of the addition of escalating doses of tumor necrosis factor (TNF) to two fixed doses and schedules of a combination of interleukin-2 (IL-2) and interferon-α (IFN-α) to determine the maximum tolerated dose of this three-cytokine combination and its feasibility as an outpatient regimen. Eighteen patients with metastatic cancer were enrolled. Each course consisted of 3 consecutive weeks of treatment with IFN-κa 9 x 106 IU/m2/day intramuscularly (i.m.) or subcutaneously (s.c.) days 1, 3, and 5 each week for 3 weeks plus IL-2 continuous infusion 1 x 106 IU/m2/day (group A) or 3 x 106 IU/m2/day (group B) days 1-5 each week for 3 weeks. TNF was administered only during the first week of each course intravenously (i.v.) for 2 h on days 1-5. The dose of TNF was escalated (40, 80, 120 μg/m2) in cohorts of 3 patients. The most common side effects were fever, chills, and fatigue in all patients. Grade 3-4 toxicity included anemia (3 patients), thrombocytopenia (1 patient), arrhythmia (2 patients), pulmonary edema (3 patients), and weight loss (1 patient). Five patients withdrew from study due to toxicity. The combination of the three cytokines is feasible as an outpatient regimen in one of the following combinations: (a) TNF 80 μg/m2/day as 2-h infusion on days 1-5 + IL-2 1 x 106 IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-κa 9 x 106 IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks, or (b) TNF 40 μg/m2/day as a 2-h infusion on days 1-5 + IL-2 3 x 106 IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-κa 9 x 106 IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks.

Original languageEnglish (US)
Pages (from-to)511-514
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume20
Issue number5
DOIs
StatePublished - Oct 1 1997

Fingerprint

Interferons
Interleukin-2
Tumor Necrosis Factor-alpha
Outpatients
Cytokines
Chills
Maximum Tolerated Dose
Interleukin-3
Pulmonary Edema
Interleukin-1
Fatigue
Cardiac Arrhythmias
Anemia
Weight Loss
Appointments and Schedules
Fever
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{d55f3aec99654755997369718e51dd10,
title = "Phase I study combining tumor necrosis factor with interferon-α and interleukin-2",
abstract = "We evaluated the effects of the addition of escalating doses of tumor necrosis factor (TNF) to two fixed doses and schedules of a combination of interleukin-2 (IL-2) and interferon-α (IFN-α) to determine the maximum tolerated dose of this three-cytokine combination and its feasibility as an outpatient regimen. Eighteen patients with metastatic cancer were enrolled. Each course consisted of 3 consecutive weeks of treatment with IFN-κa 9 x 106 IU/m2/day intramuscularly (i.m.) or subcutaneously (s.c.) days 1, 3, and 5 each week for 3 weeks plus IL-2 continuous infusion 1 x 106 IU/m2/day (group A) or 3 x 106 IU/m2/day (group B) days 1-5 each week for 3 weeks. TNF was administered only during the first week of each course intravenously (i.v.) for 2 h on days 1-5. The dose of TNF was escalated (40, 80, 120 μg/m2) in cohorts of 3 patients. The most common side effects were fever, chills, and fatigue in all patients. Grade 3-4 toxicity included anemia (3 patients), thrombocytopenia (1 patient), arrhythmia (2 patients), pulmonary edema (3 patients), and weight loss (1 patient). Five patients withdrew from study due to toxicity. The combination of the three cytokines is feasible as an outpatient regimen in one of the following combinations: (a) TNF 80 μg/m2/day as 2-h infusion on days 1-5 + IL-2 1 x 106 IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-κa 9 x 106 IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks, or (b) TNF 40 μg/m2/day as a 2-h infusion on days 1-5 + IL-2 3 x 106 IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-κa 9 x 106 IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks.",
author = "Eskander, {Elhamy D.} and Harold Harvey and Elise Givant and Allan Lipton",
year = "1997",
month = "10",
day = "1",
doi = "10.1097/00000421-199710000-00016",
language = "English (US)",
volume = "20",
pages = "511--514",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Phase I study combining tumor necrosis factor with interferon-α and interleukin-2. / Eskander, Elhamy D.; Harvey, Harold; Givant, Elise; Lipton, Allan.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 20, No. 5, 01.10.1997, p. 511-514.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase I study combining tumor necrosis factor with interferon-α and interleukin-2

AU - Eskander, Elhamy D.

AU - Harvey, Harold

AU - Givant, Elise

AU - Lipton, Allan

PY - 1997/10/1

Y1 - 1997/10/1

N2 - We evaluated the effects of the addition of escalating doses of tumor necrosis factor (TNF) to two fixed doses and schedules of a combination of interleukin-2 (IL-2) and interferon-α (IFN-α) to determine the maximum tolerated dose of this three-cytokine combination and its feasibility as an outpatient regimen. Eighteen patients with metastatic cancer were enrolled. Each course consisted of 3 consecutive weeks of treatment with IFN-κa 9 x 106 IU/m2/day intramuscularly (i.m.) or subcutaneously (s.c.) days 1, 3, and 5 each week for 3 weeks plus IL-2 continuous infusion 1 x 106 IU/m2/day (group A) or 3 x 106 IU/m2/day (group B) days 1-5 each week for 3 weeks. TNF was administered only during the first week of each course intravenously (i.v.) for 2 h on days 1-5. The dose of TNF was escalated (40, 80, 120 μg/m2) in cohorts of 3 patients. The most common side effects were fever, chills, and fatigue in all patients. Grade 3-4 toxicity included anemia (3 patients), thrombocytopenia (1 patient), arrhythmia (2 patients), pulmonary edema (3 patients), and weight loss (1 patient). Five patients withdrew from study due to toxicity. The combination of the three cytokines is feasible as an outpatient regimen in one of the following combinations: (a) TNF 80 μg/m2/day as 2-h infusion on days 1-5 + IL-2 1 x 106 IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-κa 9 x 106 IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks, or (b) TNF 40 μg/m2/day as a 2-h infusion on days 1-5 + IL-2 3 x 106 IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-κa 9 x 106 IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks.

AB - We evaluated the effects of the addition of escalating doses of tumor necrosis factor (TNF) to two fixed doses and schedules of a combination of interleukin-2 (IL-2) and interferon-α (IFN-α) to determine the maximum tolerated dose of this three-cytokine combination and its feasibility as an outpatient regimen. Eighteen patients with metastatic cancer were enrolled. Each course consisted of 3 consecutive weeks of treatment with IFN-κa 9 x 106 IU/m2/day intramuscularly (i.m.) or subcutaneously (s.c.) days 1, 3, and 5 each week for 3 weeks plus IL-2 continuous infusion 1 x 106 IU/m2/day (group A) or 3 x 106 IU/m2/day (group B) days 1-5 each week for 3 weeks. TNF was administered only during the first week of each course intravenously (i.v.) for 2 h on days 1-5. The dose of TNF was escalated (40, 80, 120 μg/m2) in cohorts of 3 patients. The most common side effects were fever, chills, and fatigue in all patients. Grade 3-4 toxicity included anemia (3 patients), thrombocytopenia (1 patient), arrhythmia (2 patients), pulmonary edema (3 patients), and weight loss (1 patient). Five patients withdrew from study due to toxicity. The combination of the three cytokines is feasible as an outpatient regimen in one of the following combinations: (a) TNF 80 μg/m2/day as 2-h infusion on days 1-5 + IL-2 1 x 106 IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-κa 9 x 106 IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks, or (b) TNF 40 μg/m2/day as a 2-h infusion on days 1-5 + IL-2 3 x 106 IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-κa 9 x 106 IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks.

UR - http://www.scopus.com/inward/record.url?scp=0030810883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030810883&partnerID=8YFLogxK

U2 - 10.1097/00000421-199710000-00016

DO - 10.1097/00000421-199710000-00016

M3 - Article

VL - 20

SP - 511

EP - 514

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -